Galapagos NV Q1 2026 Earnings Recap

Shares fell 2.4% following a mixed quarter where transformative pipeline additions and strategic partnerships failed to fully offset concerns around cautious near-term financial outlook and margin pressure.

Key Takeaways

• Entered a strategic partnership with Gilead for Ouro Medicines’ lead program, gamgertamig, a BCMA/CD3 T cell engager targeting multiple autoimmune diseases with potential registrational trials starting in 2027.
• Gamgertamig benefits from Fast Track and Orphan drug designations and has demonstrated durable complete responses with low cytokine release syndrome in early clinical data (over 60 patients).
• The deal includes a modification and partial waiver of legacy agreement terms with Gilead, enhancing financial and strategic flexibility, with Gilead’s participation exceeding prior expectations.
• Despite promising pipeline developments, the market likely reacted negatively to cautious guidance, margin pressures, or limited near-term revenue visibility implied in the broader commentary.
• Management emphasized long-term transformation over short-term gains, but investors appear unimpressed with the near-term risk profile reflected in the stock’s decline.